Lisata Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other serious diseases. The company's lead product candidate is certepetide (formerly CEND-1), an investigational drug designed to activate a novel tumor-penetrating uptake pathway. By targeting alpha-v integrins and neuropilin-1, certepetide selectively increases the permeability of tumor blood vessels and the tumor microenvironment, allowing co-administered or tethered anti-cancer regimens to penetrate solid tumors more effectively.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on rapid global registration of lead candidate certepetide in metastatic pancreatic ductal adenocarcinoma (mPDAC) while simultaneously demonstrating its effectiveness in various other solid tumors (such as cholangiocarcinoma, appendiceal cancer, and glioblastoma multiforme) in combination with standard-of-care regimens.
Expected impact: Validation of the CendR Platform technology to enhance the penetration of co-administered anti-cancer drugs into solid tumors, potentially transforming treatment outcomes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: Kuva Labs commenced a tender offer on June 10, 2026, to acquire all outstanding shares of Lisata for $4.00 per share in cash at closing plus a Contingent Value Right (CVR). The transaction is expected to close in Q3 2026.
Medium
Terms: Announced on October 8, 2025. Catalent gains worldwide, non-exclusive rights to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) developed using Catalent's SMARTag technology platform. Lisata is eligible to receive over $10 million in tiered study initiation milestone payments plus revenue sharing on future sales and partnerships.
Medium
Terms: Announced in late 2025. Alliance to utilize GATC Health's Multinomics Advanced Technology AI Drug Discovery Platform to identify new product candidates for development.